| abstract |
The present invention relates to two crystalline forms designated as form A and form B, of (βR, δR) -2 (4-fluorophenyl) - β, δ-dihydroxy-5- (1-methylethyl) -3-phenyl-4- [ (phenylamino) carbon-yl] -1H-pyrrole-1-heptanoic acid 4- (nitrooxy) butyl ester (atorvastatin 4- (nitrooxy) butyl ester), represented by the formula (I), The invention also relates to processes for the preparation of the forms A and B, to pharmaceutical compositions comprising the two forms, and to their use for treating and/or preventing acute coronary syndromes, stroke, neurodegenerative disorders, such as Alzheimer's and Parkinson's disease as well as autoimmune diseases, such as multiple sclerosis. |